Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease.
- 1 March 1995
- journal article
- Vol. 146 (3) , 688-94
Abstract
The cellular interactions of advanced glycation end products (AGEs), which have been hypothesized to contribute to the development of vascular lesions, occur, at least in part, through their binding to a novel integral membrane protein, the receptor for AGEs (RAGE). Studies of human vascular segments show that endothelial RAGE expression at the antigen and mRNA level was variable and usually at low levels in samples from healthy individuals. In contrast, patients with a range of peripheral occlusive vascular diseases, with or without underlying diabetes, demonstrated prominent enhancement of endothelial RAGE expression. Smooth muscle cells and nerves in the vessel wall showed constitutively high levels of RAGE expression that were unchanged with aging (from 1 to 92 years) or by the presence of vascular disease. These data suggest that RAGE is likely to have ligands other than AGEs, and that multiple factors in addition to AGEs impact on its expression. Taken together, our findings suggest that RAGE may contribute to the pathogenesis of a range of vascular disorders.This publication has 27 references indexed in Scilit:
- Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins.Proceedings of the National Academy of Sciences, 1994
- Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.Proceedings of the National Academy of Sciences, 1994
- Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.Proceedings of the National Academy of Sciences, 1994
- Advanced glycation end products contribute to amyloidosis in Alzheimer disease.Proceedings of the National Academy of Sciences, 1994
- Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteinsJournal of Biological Chemistry, 1994
- Angiogenic Effects of Advanced Glycation End Products of the Maillard Reaction on Cultured Human Umbilical Cord Vein Endothelial CellsBiochemical and Biophysical Research Communications, 1993
- Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.The Journal of Experimental Medicine, 1989
- Cachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue RemodelingScience, 1988
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988
- Glucosylation of human collagen in aging and diabetes mellitus.Journal of Clinical Investigation, 1980